| OA08.05LB | Development of a novel VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA09.01 | BCG.HTI2auxo.int priming vaccination enhances the HIV-1 specific T cell immune responses elicited by MVA.HTI | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA09.02 | Anti-Env antibody-independent protection of repeated intrarectal low-dose SIVmac239 challenges in rhesus macaques by vaccination inducing Gag/Vif-specific CD8+ T but not CD4+ T cells | Oral Abstract Session | Mucosal immunity |
| OA09.03 | Impact of HLA-II associated HIV-1 adaptations on vaccine-induced CD4 T-cell immune responses | Oral Abstract Session | Cellular immunity |
| OA09.04 | Applying insights from HIV to guide the development of a T-cell vaccine for SARS-CoV-2 | Oral Abstract Session | COVID research: Applying lessons from HIV prevention to SARS CoV-2 |
| OA09.05LB | Spontaneous in vivo control of HIV replication is underpinned by the cross-clade antiviral potency of HIV-specific CD8 T cells | Oral Abstract Session | Cellular immunity |
| OA10.01 | Planning for success: generating an early roadmap with global stakeholders for increasing access and uptake of new biomedical prevention products in resource-limited settings: The *Biomedical Prevention Implementation C*ollaborative (BioPIC) | Oral Abstract Session | Policy and advocacy |
| OA10.02 | Pathways to global access for novel HIV prevention technologies | Oral Abstract Session | Policy and advocacy |
| OA10.03 | Advocates' perspectives on an efficacy trial of F/TAF as PrEP for women | Oral Abstract Session | Community engagement in prevention research |
| OA10.04 | Amplifying youth voices in HIV prevention: lessons learned from a community-based adolescent health project in Durham, NC | Oral Abstract Session | Community engagement in prevention research |